Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Guardant Health Inc GH

Healthcare
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer... see more

Recent & Breaking News (NDAQ:GH)

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

Business Wire June 4, 2024

Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

Business Wire June 3, 2024

Guardant Health Named to TIME100 Most Influential Companies

Business Wire May 31, 2024

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Business Wire May 30, 2024

FDA Advisory Committee Panel Strongly Recommends Approval of Shield(TM) Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Business Wire May 23, 2024

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

Business Wire May 23, 2024

Guardant Health to Participate in Upcoming Investor Conferences

Business Wire May 22, 2024

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Business Wire May 21, 2024

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 17, 2024

Guardant Health to present real-world data supporting performance of Shield(TM) blood test for colorectal cancer screening at 2024 Digestive Disease Week

Business Wire May 16, 2024

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Business Wire May 9, 2024

Guardant Health to Participate in Upcoming Investor Conferences

Business Wire May 7, 2024

Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone

Business Wire May 7, 2024

FDA Advisory Panel Review of Guardant Health's Shield(TM) Blood Test to Screen for Colorectal Cancer to Be Held on May 23

Business Wire April 22, 2024

Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024

Business Wire April 18, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Business Wire April 3, 2024

Kuehn Law Encourages Investors of Guardant Health, Inc. to Contact Law Firm

Newsfile March 15, 2024

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 6, 2024

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Business Wire March 1, 2024

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Business Wire February 22, 2024